Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > REGULATORY
REGULATORY
- Chuikyo Recommends Add-On Fee Premiums Related to Drug Supply Issues
December 26, 2022
- PMDA to Add 4 Staff to Expand Orphan Designation Program: FY2023 Budget
December 26, 2022
- MHLW’s FY2023 Budget Totals 33.2 Trillion Yen
December 26, 2022
- Japan Cabinet OKs Record Social Security Budget for FY2023
December 26, 2022
- MHLW Panel OKs 70 More Health Damage Claims for COVID-19 Vaccines
December 26, 2022
- Japan’s Reform Timeline Sees Major Updates for Text on Drug Pricing Overhaul
December 23, 2022
- Japan Deregulation Panel Proposes Two-Step Approval Scheme for SaMD
December 23, 2022
- PMDA to Develop Overseas PR Strategy to Woo Overseas Biotechs
December 23, 2022
- MHLW to Issue Development Requests for New Indications for 6 Meds including Stivarga
December 23, 2022
- Chuikyo Reps in Face-Off over Medical Fees to Address Drug Supply Disruptions
December 22, 2022
- Japan to Cut 310 Billion Yen in Drug Spending in FY2023 Off-Year Revision: Ministers
December 22, 2022
- Special PMP Increase to Offset 95% of Price Cuts for 150 Products: FY2023 Revision
December 22, 2022
- Japan Designates Antibiotics as Key Resources for Economic Security
December 21, 2022
- LDP Health Panel OKs FY2023 Budget Plan; MHLW Gives “Low 300-Billion-Yen Range” for Drug Cost Cut
December 20, 2022
- Still No Serious Safety Concerns with COVID-19 Vaccines: MHLW Panels
December 20, 2022
- LDP Lawmakers Give Certain Credit to FY2023 Price Revision Plan
December 20, 2022
- Susmed’s Insomnia App in Line for Approval as Early as January
December 20, 2022
- Healthcare Providers Rap Product Coverage of Off-Year Re-Pricing, Payers Hail Threshold: Chuikyo
December 19, 2022
- Orphan Drug Tag Granted for Takeda’s Maralixibat and More
December 19, 2022
- Ruling Parties OK FY2023 Tax Reform Outline; No More Special COVID Measure for R&D Credits
December 19, 2022
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…